Innate Pharma
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $-2,073 | $1,107 | $4,860 | $276 |
Gross Profit | 18,447 | -15,660 | 29,352 | |
EBITDA | -30,705 | -30,705 | -25,061 | -21,348 |
EBIT | -31,377 | -31,377 | -25,427 | -22,592 |
Net Income | -27,626 | -27,626 | -21,344 | -24,707 |
Net Change In Cash | -2,073 | 1,107 | 4,860 | 276 |
Free Cash Flow | -23,480 | -23,480 | -31,222 | -10,040 |
Cash | 28,080 | 28,080 | 53,704 | 66,396 |
Basic Shares | 91,412 | 91,412 | 86,936 | 81,052 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,787 | $12,621 | $51,901 | $57,674 |
Gross Profit | 2,787 | 12,621 | 5,619 | 6,011 |
EBITDA | -43,646 | -46,911 | -1,839 | -12,279 |
EBIT | -48,737 | -48,905 | -6,930 | -57,684 |
Net Income | -47,236 | -49,471 | -7,570 | -58,103 |
Net Change In Cash | 2,787 | 12,621 | 51,901 | 57,674 |
Free Cash Flow | -50,807 | -7,287 | -34,909 | -20,276 |
Cash | 28,080 | 66,396 | 70,605 | 84,225 |
Basic Shares | 89,415 | 81,052 | 84,111 | 79,639 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | $0 |
2025-09-30 | -$0.14 |
2025-06-30 | -$0.29 |
2025-03-31 | -$0.30 |
